Dakota Wealth Management Sells 7,964 Shares of Zoetis Inc. $ZTS

Dakota Wealth Management reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 14.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 47,594 shares of the company’s stock after selling 7,964 shares during the quarter. Dakota Wealth Management’s holdings in Zoetis were worth $5,988,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares in the last quarter. Global Wealth Strategies & Associates bought a new stake in Zoetis in the fourth quarter valued at $25,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the third quarter valued at $31,000. Holos Integrated Wealth LLC purchased a new position in Zoetis during the 4th quarter valued at $32,000. Finally, Board of the Pension Protection Fund purchased a new position in Zoetis during the 4th quarter valued at $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. UBS Group set a $136.00 target price on shares of Zoetis in a research report on Thursday, January 29th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Bank of America increased their price target on shares of Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. BTIG Research reaffirmed a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Finally, William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Six investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $152.91.

Zoetis Stock Performance

ZTS stock opened at $113.48 on Friday. The stock’s 50 day simple moving average is $123.39 and its 200 day simple moving average is $129.31. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. Zoetis Inc. has a 12-month low of $113.29 and a 12-month high of $172.23. The stock has a market capitalization of $47.90 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 1.78 and a beta of 0.95.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter in the previous year, the firm earned $1.40 EPS. Zoetis’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio is 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.